AtriCure Names David Francischelli as Vice President of Research and Development

  AtriCure Names David Francischelli as Vice President of Research and

Business Wire

WEST CHESTER, Ohio -- June 24, 2013

AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in the
development of technologies and solutions for the treatment of atrial
fibrillation, or Afib, and systems for the exclusion of the left atrial
appendage, today announced that David Francischelli has joined the company as
Vice President of Research and Development, effective August 6, 2013.

Mr. Francischelli is an accomplished innovator in the medical device industry
with over 23 years of experience. Mr. Francischelli has spent much of his
career at Medtronic, Inc. in various research capacities; most recently as
Director of Research and Development in the company’s Structural Heart
business. In this role, he directed all aspects of research and development
for radiofrequency and cryogenic surgical ablation technologies; including
novel disposable devices and capital equipment systems, developing new
approaches to lesion creation and evaluating areas for new therapy
applications. Previously, Mr. Francischelli lead research functions for
Medtronic’s Atrial Fibrillation and Cardiac Assist Systems sectors. During his
tenure at Medtronic, Mr. Francischelli developed the Cardioblate irrigated
ablation system, which has treated over 150,000 patients worldwide. In
addition to these accomplishments, Mr. Francischelli has been granted over 50
patents, with an additional 80 more pending. He was recently named as a 2013
Top Inventor by Twin Cities Business.

"David is a proven leader with a strong record of business and product
innovations spanning over twenty years. His experience with atrial
fibrillation and ablation technologies will be invaluable as we strive to lead
the industry in the treatment of AFib. We could not ask for a better fit for
the role, and are thrilled to have David aboard,” said Mike Carrel, President
and Chief Executive Officer of AtriCure.

David will report directly to Mike Carrel and be a member of the AtriCure
Executive Leadership Team.

“I have worked with David Francischelli for over a decade, and I am thrilled
he is joining AtriCure. David is an innovative leader and talented engineer in
the atrial fibrillation space and will be a great addition to the already
strong team at AtriCure,” said Dr. Ralph Damiano, Chief of Cardiac Surgery at
Washington University School of Medicine.

About AtriCure, Inc.
AtriCure, Inc. is a medical device company providing innovative Atrial
Fibrillation (Afib) solutions designed to produce superior outcomes that
reduce the economic and social burden of Atrial Fibrillation. AtriCure’s
Synergy Ablation System is the first and only device approved for the
treatment of Persistent and Longstanding Persistent forms of Afib in patients
undergoing certain open concomitant procedures. AtriCure’s AtriClip Left
Atrial Appendage (LAA) exclusion device is the most widely implanted device
for LAA management worldwide.The company believes cardiothoracic surgeons are
adopting its ablation and LAA management devices for the treatment of Afib and
reduction of Afib related complications such as stroke. Afib affects more than
5.5 million people worldwide.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements that address activities, events or developments
that AtriCure expects, believes or anticipates will or may occur in the
future, such as earnings estimates, other predictions of financial
performance, launches by AtriCure of new products and market acceptance of
AtriCure’s products. Forward-looking statements are based on AtriCure’s
experience and perception of current conditions, trends, expected future
developments and other factors it believes are appropriate under the
circumstances and are subject to numerous risks and uncertainties, many of
which are beyond AtriCure’s control. These risks and uncertainties include the
rate and degree of market acceptance of AtriCure’s products, AtriCure’s
ability to develop and market new and enhanced products, the timing of and
ability to obtain and maintain regulatory clearances and approvals for its
products, the timing of and ability to obtain reimbursement of procedures
utilizing AtriCure’s products, competition from existing and new products and
procedures or AtriCure’s ability to effectively react to other risks and
uncertainties described from time to time in AtriCure’s SEC filings, such as
fluctuation of quarterly financial results, reliance on third party
manufacturers and suppliers, litigation or other proceedings, government
regulation and stock price volatility. AtriCure does not guarantee any
forward-looking statement, and actual results may differ materially from those
projected. AtriCure undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information, future
events or otherwise.


AtriCure, Inc.
Andy Wade, 513-755-4564
Vice President and Chief Financial Officer
Investor Relations Contact:
Westwicke Partners
Lynn Pieper, 415-202-5678
Press spacebar to pause and continue. Press esc to stop.